Levosimendan Pretreatment for Weaning Patients From Cardio-Pulmonary Bypass

This study has been completed.
Sponsor:
Information provided by:
Orion Corporation, Orion Pharma
ClinicalTrials.gov Identifier:
NCT00130871
First received: August 15, 2005
Last updated: February 19, 2007
Last verified: February 2007

August 15, 2005
February 19, 2007
January 2004
Not Provided
Proportion of successful primary weanings
Same as current
Complete list of historical versions of study NCT00130871 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Levosimendan Pretreatment for Weaning Patients From Cardio-Pulmonary Bypass
Impact of Levosimendan Pretreatment on Weaning From Cardiopulmonary Bypass (CPB) in Patients With Diminished Left Ventricular Function Before Coronary Artery Bypass Grafting (CABG)

The study evaluates the efficacy of intravenous levosimendan treatment started during a coronary artery bypass operation to wean patients from a heart lung machine.

Levosimendan or placebo infusion is started at the time of induction of anesthesia.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Coronary Heart Disease
Drug: levosimendan
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
60
January 2006
Not Provided

Inclusion Criteria:

  • Three vessel coronary artery disease.
  • Indication for on-pump coronary artery bypass surgery.
  • Ejection fraction below 50%

Exclusion Criteria:

  • Indication for any cardiac valve surgery
  • Previous coronary artery bypass surgery
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Finland
 
NCT00130871
3001079
Not Provided
Not Provided
Orion Corporation, Orion Pharma
Not Provided
Principal Investigator: Markku Salmenperä, MD Helsinki University Central Hospital, Finland
Orion Corporation, Orion Pharma
February 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP